AlphaGalileo is a service for the media.
Journalists should register for free access to embargoed
news and press office contact information.
Please register view details
Please register to view contact details
Please log in or register to view articles older than 3 months
This item is under embargo and is only visible to journalists
Bookmark this item in My Area
This item is bookmarked
Add comments to this news release
Cannabis-based medications have been proved to relieve pain. This is the conclusion drawn by Franjo Grotenhermen and Kirsten Müller-Vahl in issue 29–30 of Deutsches Ärzteblatt International.
Cannabis medications can be used in patients whose symptoms are not adequately alleviated by conventional treatment. The indications are muscle spasms, nausea and vomiting as a result of chemotherapy, loss of appetite in HIV/Aids, and neuropathic pain.
The clinical effect of the various cannabis-based medications rests primarily on activation of endogenous cannabinoid receptors. Consumption of therapeutic amounts by adults does not lead to irreversible cognitive impairment. The risk is much greater, however, in children and adolescents (particularly before puberty), even at therapeutic doses.
Over 100 controlled trials of the effects of cannabinoids in various indications have been carried out since 1975. The positive results have led to official licensing of cannabis-based medications in many countries. In Germany, a cannabis extract was approved in 2011 for treatment of spasticity in multiple sclerosis. In June 2012 the Federal Joint Committee (the highest decision-making body for the joint self-government of physicians, dentists, hospitals and health insurance funds in Germany) pronounced that the cannabis extract showed a slight additional benefit for this indication and granted a temporary license until 2015.
Franjo Grotenhermen, Kirsten Müller-Vahl, The Therapeutic Potential of Cannabis and Cannabinoids, Deutsches Ärzteblatt International | Dtsch Arztebl Int 2012; 109(29–30): 495–501
This item has been withdrawn. Registered users can contact the publishing organisation for further details by logging in